GlassScriptPhysician profile
Andrew M Benton
NPI 1336553858
$7,562.36
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $1,131 · 2021: $2,261 · 2022: $721 · 2023: $1,398 · 2024: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,910.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,776.25 | 2020-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,139.62 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $448.89 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $421.12 | 2019-2024 | Zepbound, Mounjaro, Emgality |
| Pfizer INC. | $347.42 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $335.71 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Biohaven Pharmaceuticals, INC. | $303.30 | 2020-2021 | |
| Allergan, INC. | $294.51 | 2019-2021 | |
| Amgen INC. | $246.18 | 2020-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $228.23 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $218.54 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $154.51 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.37 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.50 | 2019-2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $120.98 | 2019-2024 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.